On the public citation graph

Affordable orphan drugs: a role for not‐for‐profit organizations

0 signed · 75 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.drudis.2008.02.005openalex-snapshot
Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions
inferredcites →https://doi.org/10.1016/j.drudis.2012.02.005openalex-snapshot
Orphan drug development: an economically viable strategy for biopharma R&D
inferredcites →https://doi.org/10.1016/j.drudis.2013.11.009openalex-snapshot
Financing drug discovery for orphan diseases
inferredcites →https://doi.org/10.1016/j.drudis.2016.07.002openalex-snapshot
What will the crowd fund? Preferences of prospective donors for drug development fundraising campaigns
inferredcites →https://doi.org/10.1016/j.healthpol.2010.12.002openalex-snapshot
The cost of drug development: A systematic review
inferredcites →https://doi.org/10.1016/j.jhealeco.2016.01.012openalex-snapshot
Innovation in the pharmaceutical industry: New estimates of R&D costs
inferredcites →https://doi.org/10.1016/j.respol.2006.12.006openalex-snapshot
Orphan drugs: Unmet societal need for non-profitable privately supplied new products
inferredcites →https://doi.org/10.1038/536388aopenalex-snapshot
Busting the billion-dollar myth: how to slash the cost of drug development
inferredcites →https://doi.org/10.1038/nbt.2786openalex-snapshot
Clinical development success rates for investigational drugs
inferredcites →https://doi.org/10.1038/nrd1468openalex-snapshot
Drug repositioning: identifying and developing new uses for existing drugs
inferredcites →https://doi.org/10.1038/nrd4232openalex-snapshot
Where do new medicines originate from in the EU?
inferredcites →https://doi.org/10.1093/qjmed/hci128openalex-snapshot
Drugs for exceptionally rare diseases: do they deserve special status for funding?
inferredcites →https://doi.org/10.1111/bcp.13240openalex-snapshot
Affordable orphan drugs: a role for not‐for‐profit organizations
inferredcites →https://doi.org/10.1136/bmj.39055.610764.47openalex-snapshot
Getting new drugs to market: how individuals could do this without leaving their desks
inferredcites →https://doi.org/10.1136/bmj.g1445openalex-snapshot
Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding
inferredcites →https://doi.org/10.1136/bmjopen-2014-007199openalex-snapshot
Effectiveness, safety and costs of orphan drugs: an evidence-based review
inferredcites →https://doi.org/10.1186/s13023-015-0305-yopenalex-snapshot
The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
inferredcites →https://doi.org/10.1186/s40545-016-0064-8openalex-snapshot
Upstream solutions for price-gouging on critical generic medicines
inferredcites →https://doi.org/10.1371/journal.pone.0164681openalex-snapshot
Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study
inferredcites →https://doi.org/10.1377/hlthaff.2014.1038openalex-snapshot
The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs
inferredcites →https://doi.org/10.1377/hlthaff.24.4.1057openalex-snapshot
Oxymoron No More: The Potential Of Nonprofit Drug Companies To Deliver On The Promise Of Medicines For The Developing World
inferredcites →https://doi.org/10.1517/21678707.2013.796883openalex-snapshot
Repurposing as a strategy for orphan drug development, evidence from European approvals
inferredcites →https://doi.org/10.3390/medicina43060054openalex-snapshot
Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4779040openalex-extracted
Success of Drug Development for Cancer Diseases: Radicalness and Structural Holes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.8330openalex-snapshot
Rare Disease Drug Repurposing
inferred← citeshttps://doi.org/10.1016/b978-0-12-822211-9.00002-2openalex-snapshot
Pharmaceutical regulatory requirements of nonregulated markets
inferred← citeshttps://doi.org/10.1016/j.coph.2022.102201openalex-snapshot
Precision medicine for rare diseases: The times they are A-Changin'
inferred← citeshttps://doi.org/10.1016/j.drudis.2022.103342openalex-snapshot
Emergent treatments for β-thalassemia and orphan drug legislations
inferred← citeshttps://doi.org/10.1016/j.drudis.2026.104631openalex-snapshot
Tracing the path of non-industry-driven medicine development for rare diseases through regulatory interactions at the European Medicines Agency
inferred← citeshttps://doi.org/10.1016/j.healthpol.2017.09.005openalex-snapshot
A review of international coverage and pricing strategies for personalized medicine and orphan drugs
inferred← citeshttps://doi.org/10.1016/j.semcancer.2020.01.008openalex-snapshot
Repurposing drugs in oncology: From candidate selection to clinical adoption
inferred← citeshttps://doi.org/10.1016/j.techfore.2020.120333openalex-snapshot
Opportunities and barriers for innovation and entrepreneurship in orphan drug development
inferred← citeshttps://doi.org/10.1016/j.therap.2020.02.006openalex-snapshot
Drug repurposing in rare diseases: Myths and reality
inferred← citeshttps://doi.org/10.1016/j.tips.2018.03.003openalex-snapshot
Orphan Drugs and Their Impact on Pharmaceutical Development
inferred← citeshttps://doi.org/10.1016/j.tips.2021.01.003openalex-snapshot
Drug Repurposing for Rare Diseases
inferred← citeshttps://doi.org/10.1016/j.vhri.2023.01.003openalex-snapshot
Exploring the Potential Challenges for Developing Generic Orphan Drugs for Rare Diseases: A Survey of US and European Markets
inferred← citeshttps://doi.org/10.1017/beq.2022.9openalex-snapshot
Free Markets and Public Interests in the Pharmaceutical Industry: A Comparative Analysis of Catholic and Reformational Critiques of Neoliberal Thought
inferred← citeshttps://doi.org/10.1038/nrclinonc.2017.69openalex-snapshot
Scientific advice — is drug repurposing missing a trick?
inferred← citeshttps://doi.org/10.1080/21678707.2021.1913121openalex-snapshot
The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways
inferred← citeshttps://doi.org/10.1101/2022.12.22.22283870openalex-snapshot
Assessing the availability of Repurposed Orphan Drugs in India
inferred← citeshttps://doi.org/10.1111/bcp.13331openalex-snapshot
Drugs for rare disorders
inferred← citeshttps://doi.org/10.1111/bcp.14295openalex-snapshot
Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?
inferred← citeshttps://doi.org/10.1111/bph.70243openalex-snapshot
The eyes of the beholder: Perceived barriers to successful drug repurposing
inferred← citeshttps://doi.org/10.1163/15718093-bja10005openalex-snapshot
Introducing ‘Health Vulnerability’. Towards a Human Right Claim for Innovative Orphan Drugs?
inferred← citeshttps://doi.org/10.1177/22146490261486345openalex-snapshot
Reinvigorating the possibilities: Drug repurposing as a strategic access pathway for rare diseases
inferred← citeshttps://doi.org/10.1186/s13023-017-0741-yopenalex-snapshot
Compounded medication for patients with rare diseases
inferred← citeshttps://doi.org/10.1186/s13023-024-03095-zopenalex-snapshot
Trends in orphan medicinal products approvals in the European Union between 2010–2022
inferred← citeshttps://doi.org/10.1186/s13023-025-04035-1openalex-snapshot
Mitigating the impact of study-start delays in clinical trials for rare disorders: insights and lessons from a PKAN trial
inferred← citeshttps://doi.org/10.1186/s13023-026-04367-6openalex-snapshot
Access to orphan drugs in adults with inherited metabolic diseases in Switzerland: a single-center retrospective cohort study
inferred← citeshttps://doi.org/10.1186/s13023-026-04551-8openalex-snapshot
Navigating regulatory scenarios for accelerating drug repurposing in rare diseases: a multi-stakeholder perspective on the challenges and opportunities
inferred← citeshttps://doi.org/10.1186/s13063-021-05273-xopenalex-snapshot
Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research
inferred← citeshttps://doi.org/10.1186/s13584-024-00635-7openalex-snapshot
Chronically ill patients’ perspectives on support services and activities of patient organizations
inferred← citeshttps://doi.org/10.12688/f1000research.130388.1openalex-snapshot
Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan
inferred← citeshttps://doi.org/10.12688/f1000research.130388.2openalex-snapshot
Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan
inferred← citeshttps://doi.org/10.12688/f1000research.130809.1openalex-snapshot
Pharmaceutical policy and innovation for rare diseases: A narrative review
inferred← citeshttps://doi.org/10.12688/f1000research.130809.2openalex-snapshot
Pharmaceutical policy and innovation for rare diseases: A narrative review
inferred← citeshttps://doi.org/10.1371/journal.pgph.0001498openalex-snapshot
Assessment of the availability of repurposed orphan drugs in India
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2341132/v1openalex-snapshot
Chronically ill Patients’ Perspectives on Support Services and Activities of Patient Organizations
inferred← citeshttps://doi.org/10.3389/fmed.2021.817663openalex-snapshot
Repurposing of Medicines in the EU: Launch of a Pilot Framework
inferred← citeshttps://doi.org/10.3389/fonc.2017.00273openalex-snapshot
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
inferred← citeshttps://doi.org/10.3389/fphar.2019.01664openalex-snapshot
On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
inferred← citeshttps://doi.org/10.3389/fphar.2021.738458openalex-snapshot
Orphan Drugs, Compounded Medication and Pharmaceutical Commons
inferred← citeshttps://doi.org/10.3389/fphar.2021.746987openalex-snapshot
Drug Repurposing for Rare Diseases: A Role for Academia
inferred← citeshttps://doi.org/10.3389/fphar.2022.869842openalex-snapshot
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
inferred← citeshttps://doi.org/10.3389/fphar.2023.1142351openalex-snapshot
Access to medicines for rare diseases: A European regulatory roadmap for academia
inferred← citeshttps://doi.org/10.3389/fpubh.2021.754482openalex-snapshot
Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers
inferred← citeshttps://doi.org/10.3390/ijerph17092991openalex-snapshot
Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007–2019)
inferred← citeshttps://doi.org/10.3390/ijerph192013319openalex-snapshot
A Cross-Sectional Study of Price and Affordability of Drugs for Rare Diseases in Shandong Province, China
inferred← citeshttps://doi.org/10.4103/ijp.ijp_979_25openalex-snapshot
Orphan drugs: The final frontier in the fight against rare diseases
inferred← citeshttps://doi.org/10.5301/maapoc.0000016openalex-snapshot
From Off-Label to Repurposed Drug in Non-Oncological Rare Diseases: Definition and State of the Art in Selected EU Countries
inferred← citeshttps://doi.org/10.53730/ijhs.v4ns1.15020openalex-snapshot
Regulatory challenges in pharmaceuticals: Navigating global compliance and approval
inferred← citeshttps://doi.org/10.6084/m9.figshare.14538717openalex-snapshot
Additional file 1 of Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research
inferred← citeshttps://doi.org/10.6084/m9.figshare.14538720openalex-snapshot
Additional file 2 of Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research
inferred← citeshttps://doi.org/10.6084/m9.figshare.27042498openalex-snapshot
Additional file 1 of Chronically ill patients’ perspectives on support services and activities of patient organizations
showing the first 51 of 52 · page through all 52
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.